Understand the source comparison
Best Peptides for Raynaud's Syndrome: Research Comparison
BPC-157 VEGF upregulation, angiogenesis Promotes new capillary formation in ischemic tissue. Addresses progressive microvascular damage Preclinical animal models; no human Raynaud's trials Requires daily subcutaneous injection; effects accumulate over 4–8 week
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis
- Promotes new capillary formation in ischemic tissue. Addresses progressive microvascular damage
- Preclinical animal models; no human Raynaud's trials
- Requires daily subcutaneous injection; effects accumulate over 4–8 weeks
- Thymosin Beta-4
- Actin polymerization, endothelial cell migration
- Accelerates repair of damaged vessel walls; increases capillary density
- Phase I/II trials in cardiovascular contexts; no Raynaud's-specific studies
- Dosing typically 2–3×/week; synergistic with BPC-157 in vascular models
- GHRP-2
- GH secretagogue, indirect eNOS upregulation
- Enhances nitric oxide bioavailability through IGF-1 pathway
- Established GH-releasing effects; vascular benefits extrapolated from IGF-1 research
- Must be administered fasted; GH spikes may affect glucose metabolism
- Ipamorelin
- Selective GH secretagogue
- Similar to GHRP-2 but without cortisol elevation
- More selective than GHRP-2; same vascular mechanism
- Preferred for long-term protocols due to hormonal selectivity
- Thymalin
- Immune modulation, cytokine regulation
- Targets immune-mediated endothelial damage in secondary Raynaud's
- Clinical trials in autoimmune diseases; improvements in microcirculation documented
- Most relevant for autoimmune-associated Raynaud's; less applicable to primary form